Why the study?
A single thrombolytic agent for all indications in acute ischaemic stroke is desirable to streamline workflows.
Does tenecteplase improve outcomes compared to alteplase in patients with acute ischaemic stroke?
Does tenecteplase improve outcomes compared to alteplase in patients with acute ischaemic stroke?
Tenecteplase is emerging as a potential alternative to alteplase for thrombolysis in acute ischaemic stroke, which could streamline clinical workflows.
Answers are grounded in this paper and cite their sources.
May support tenecteplase as alteplase alternative for workflow efficiency; leaves open definitive phase 3 confirmation.
A single thrombolytic agent for all indications for thrombolysis in acute ischaemic stroke is desirable in streamlining workflows. Based on recent and upcoming trials, guidelines may soon recommend tenecteplase as a suitable alternative to alteplase. The use of tenecteplase in specific subgroups will depend on further recruitment to ongoing clinical trials.
No takes yet. Share an insight, caveat, or question.
Mahmood et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: